Wall Street Zen Downgrades SAB Biotherapeutics to Sell Rating

The biotech company's stock price drops after the rating change.

Mar. 14, 2026 at 6:04am

Got story updates? Submit your updates here. ›

Wall Street Zen, an investment research firm, has downgraded SAB Biotherapeutics (NASDAQ:SABS) from a "hold" rating to a "sell" rating in a new report. The downgrade comes as the company's stock price has declined in recent months, with the stock currently trading around $4.15 per share.

Why it matters

The rating change from Wall Street Zen could impact investor sentiment and trading activity around SAB Biotherapeutics' stock. Downgrades from analysts can sometimes lead to further stock price declines, as investors may lose confidence in the company's prospects. This news is significant for the company and its shareholders.

The details

In their report, Wall Street Zen cited concerns about SAB Biotherapeutics' financial performance and future outlook. The firm lowered its price target for the stock from $9.00 to $7.00, while maintaining a "buy" rating. Other analysts have also issued mixed reviews of the company, with one firm giving it a "strong buy" rating and another issuing a "sell" recommendation.

  • SAB Biotherapeutics' stock price closed at $4.15 on Friday, March 14, 2026.

The players

Wall Street Zen

An investment research firm that provides analysis and ratings on public companies.

SAB Biotherapeutics

A clinical-stage biotechnology company focused on developing fully human polyclonal antibody therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“We must downgrade SAB Biotherapeutics to a 'sell' rating due to concerns about the company's financial performance and future outlook.”

— Wall Street Zen, Investment Research Firm

What’s next

Investors will be closely watching to see how SAB Biotherapeutics' stock price reacts to the rating downgrade and whether the company can address the concerns raised by Wall Street Zen.

The takeaway

This rating change highlights the volatility and uncertainty surrounding SAB Biotherapeutics' stock, as the company navigates the challenges of the biotech industry and seeks to develop its innovative antibody therapies.